VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
RBOTVicarious Surgical Inc.
$0.20$1M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksRBOTP/E History

RBOT logoVicarious Surgical Inc. (RBOT) P/E Ratio History

Deep Value

Trading at -0.0x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2022–2022

Current P/E (TTM)
-0.0x
-100% vs 5Y avg
5Y Avg P/E
24.6x
Median 14.3x
5Y Percentile
0th
Lower end of range
PEG Ratio
N/A
5-Year P/E Range
-0.0x
Min4.7xMedian14.3xMax72.1x
TTM EPS$-6.29
Price$0.20
Earnings YieldN/A
EPS Growth (1Y)21.2%
EPS Growth (5Y)N/A

Loading P/E history...

P/E Ratio Analysis

As of June 23, 2026, Vicarious Surgical Inc. (RBOT) trades at a price-to-earnings ratio of -0.0x, with a stock price of $0.20 and trailing twelve-month earnings per share of $-6.29.

The current P/E is 100% below its 5-year average of 24.6x. Over the past five years, RBOT's P/E has ranged from a low of 4.7x to a high of 72.1x, placing the current valuation at the 0th percentile of its historical range.

Compared to the Healthcare sector median P/E of 22.1x, RBOT trades at a 100% discount to its sector peers. The sector includes 233 companies with P/E ratios ranging from 0.0x to 194.5x.

Relative to the broader market, RBOT trades at a notable discount to the S&P 500 median P/E of 24.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our RBOT DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

RBOT Cross-Benchmark Valuation

How does the current P/E compare to sector peers and the broader market?

vs. Healthcare
-0.0vs22.1
-100%
Below Sector
vs. S&P 500
-0.0vs24.3
-100%
Below Market
PEG Analysis
N/A
P/E ÷ EPS Growth
Based on 21% EPS growth (1Y)

RBOT P/E vs Peers

Surgical tools, endoscopy, and robotics peers sorted by market cap

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
ISRG logoISRGIntuitive Surgical, Inc.
$143B51.22.37+23%
SYK logoSYKStryker Corporation
$117B36.32.46+8%
MDT logoMDTMedtronic plc
$102B22.0-+31%
GMED logoGMEDGlobus Medical, Inc.
$11B20.20.65+423%Best
ABT logoABTAbbott Laboratories
$153B11.5Lowest0.39Best+134%
BSX logoBSXBoston Scientific Corporation
$66B22.9-+55%

Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.

RBOT Historical P/E Data (2022–2022)

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterPeriod EndPriceTTM EPSP/E Ratiovs Avg
FY2022 Q4Dec 31 2022$60.60$0.8472.1x+194%
FY2022 Q3Sep 30 2022$100.50$21.214.7x-81%
FY2022 Q2-$88.20$12.517.1x-71%
FY2022 Q1-$151.80$10.6014.3x-42%

Average P/E for displayed period: 24.6x

Export Data
Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

4+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

RBOT — Frequently Asked Questions

Quick answers to the most common questions about buying RBOT stock.

What is RBOT's P/E ratio?

Vicarious Surgical Inc. (RBOT) trailing twelve-month P/E ratio is -0.0x, based on TTM diluted EPS of $-6.29. The 5-year average P/E is 24.6x and the historical range spans 4.7x to 72.1x.

Is RBOT stock overvalued or undervalued?

RBOT current P/E: -0.0x. 5-year average P/E: 24.6x. Percentile: 0th.

Is RBOT stock expensive?

RBOT is fairly valued relative to its own history. The current P/E of -0.0x is near the 5-year average of 24.6x (0th percentile of historical range).

What is RBOT's historical P/E range?

Over the past 5 years, RBOT's P/E ratio has ranged from 4.7x to 72.1x, with a median of 14.3x and an average of 24.6x. The current P/E of -0.0x places the stock at the 0th percentile of this range. Full historical data spans 2022–2022.

How does RBOT's P/E compare to the S&P 500?

RBOT current P/E: -0.0x. S&P 500 median P/E: 24.3x.

How does RBOT's valuation compare to Healthcare peers?

Vicarious Surgical Inc. P/E of -0.0x can be benchmarked against Healthcare peers in the comparison table on this page.

What is RBOT's PEG ratio?

RBOT PEG ratio is N/A, based on a P/E of -0.0x and EPS growth of 21.2%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.

What is RBOT's earnings yield?

RBOT earnings yield is N/A, the inverse of its -0.0x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.

RBOT P/E Ratio History (2022–2022)

Quarterly valuation multiple from closing price and trailing EPS

Current72.1x
Period Avg24.6x
Range4.7x - 72.1x
Change+404%
4 quartersMar 31, 2022 - Dec 31, 2022